|
Section 201.1
|
Drugs and devices; National Drug Code numbers |
|
Section 201.2
|
Drugs; adequate directions for use |
|
Section 201.5
|
Drugs; misleading statements |
|
Section 201.6
|
Drugs; statement of ingredients |
|
Section 201.10
|
Drugs; prominence of required label statements |
|
Section 201.15
|
Drugs; Spanish-language version of certain required statements |
|
Section 201.16
|
Drugs; location of expiration date |
|
Section 201.17
|
Drugs; significance of control numbers |
|
Section 201.18
|
Drugs; use of term ``infant'' |
|
Section 201.19
|
Declaration of presence of FD&C; Yellow No |
|
Section 201.20
|
Declaration of presence of phenylalanine as a component of aspartame in over-the-counter and prescription drugs for human use |
|
Section 201.21
|
Prescription drugs containing sulfites; required warning statements |
|
Section 201.22
|
Required pediatric studies |
|
Section 201.23
|
Labeling for systemic antibacterial drug products |
|
Section 201.24
|
Bar code label requirements |
|
Section 201.25
|
Exceptions or alternatives to labeling requirements for human drug products held by the Strategic National Stockpile |
|
Section 201.26
|
Statement of identity |
|
Section 201.50
|
Declaration of net quantity of contents |
|
Section 201.51
|
Statement of dosage |
|
Section 201.55
|
Requirements on content and format of labeling for human prescription drug and biological products |
|
Section 201.56
|
Specific requirements on content and format of labeling for human prescription drug and biological products described in |
|
Section 201.57
|
Specific requirements on content and format of labeling for human prescription drug and biological products described |
|
Section 201.57
|
Waiver of labeling requirements |
|
Section 201.58
|
Principal display panel |
|
Section 201.60
|
Statement of identity |
|
Section 201.61
|
Declaration of net quantity of contents |
|
Section 201.62
|
Pregnancy/breast-feeding warning |
|
Section 201.63
|
Sodium labeling |
|
Section 201.64
|
Format and content requirements for over-the-counter (OTC) drug product labeling |
|
Section 201.66
|
Calcium labeling |
|
Section 201.70
|
Magnesium labeling |
|
Section 201.71
|
Potassium labeling |
|
Section 201.72
|
Specific requirements on content and format of labeling for human prescription drug and biological products; older drugs not |
|
Section 201.80
|
Prescription drugs for human use |
|
Section 201.100
|
Veterinary drugs |
|
Section 201.105
|
New drugs or new animal drugs |
|
Section 201.115
|
Drugs having commonly known directions |
|
Section 201.116
|
Inactive ingredients |
|
Section 201.117
|
In vitro diagnostic products |
|
Section 201.119
|
Prescription chemicals and other prescription components |
|
Section 201.120
|
Drugs for processing, repacking, or manufacturing |
|
Section 201.122
|
Drugs for use in teaching, law enforcement, research, and analysis |
|
Section 201.125
|
Drugs; expiration of exemptions |
|
Section 201.127
|
Meaning of ``intended uses'' |
|
Section 201.128
|
Drugs; exemption for radioactive drugs for research use |
|
Section 201.129
|
Drugs; processing, labeling, or repacking |
|
Section 201.150
|
Carbon dioxide and certain other gases |
|
Section 201.161
|
Disclosure of drug efficacy study evaluations in labeling and advertising |
|
Section 201.200
|
Notice to manufacturers, packers, and distributors of glandular preparations |
|
Section 201.300
|
Notice to manufacturers, packers, and distributors of estrogenic hormone preparations |
|
Section 201.301
|
Notice to manufacturers, packers, and distributors of drugs for internal use which contain mineral oil |
|
Section 201.302
|
Labeling of drug preparations containing significant proportions of wintergreen oil |
|
Section 201.303
|
Tannic acid and barium enema preparations |
|
Section 201.304
|
Isoproterenol inhalation preparations (pressurized aerosols, nebulizers, powders) for human use; warnings |
|
Section 201.305
|
Potassium salt preparations intended for oral ingestion by man |
|
Section 201.306
|
Sodium phosphates; package size limitation, warnings, and directions for over-the-counter sale |
|
Section 201.307
|
Ipecac syrup; warnings and directions for use for over-the-counter sale |
|
Section 201.308
|
Acetophenetidin (phenacetin)-containing preparations; necessary warning statement |
|
Section 201.309
|
Phenindione; labeling of drug preparations intended for use by man |
|
Section 201.310
|
Magnesium sulfate heptahydrate; label declaration on drug products |
|
Section 201.312
|
Estradiol labeling |
|
Section 201.313
|
Labeling of drug preparations containing salicylates |
|
Section 201.314
|
Over-the-counter drugs for minor sore throats; suggested warning |
|
Section 201.315
|
Drugs with thyroid hormone activity for human use; required warning |
|
Section 201.316
|
Digitalis and related cardiotonic drugs for human use in oral dosage forms; required warning |
|
Section 201.317
|
Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including, but not limited to agar, alginic acid, calcium |
|
Section 201.319
|
Warning statements for drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting |
|
Section 201.320
|
Aluminum in large and small volume parenterals used in total parenteral nutrition |
|
Section 201.323
|
Over-the-counter drugs for vaginal contraceptive and spermicide use containing nonoxynol 9 as the active ingredient; required |
|
Section 201.325
|
Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and |
|
Section 201.326
|
Over-the-counter sunscreen drug products; required labeling based on effectiveness testing |
|
Section 201.327
|
Prescription-drug advertisements |